We’ve hit 200,000 COVID deaths in 6 months. What will the next 6 months look like?
Experts weigh in on what the future may hold amid the pandemic. — ABC News: Top Stories
Healthcare, News Now!
Category: Healthcare
How are you feeling today? Keep up to date on news and stories related to healthcare here!
Healthcare, News Now!
Woman, 102, beats coronavirus after surviving cancer, 1918 flu pandemic
The novel coronavirus was apparently no match for a 102-year-old woman in New Hampshire. FOX News: Madeline Farber
Healthcare, News Now!
Live Covid-19 updates
Clinical trials have not included children, so vaccines for them may not arrive until the next school year, while adults may get theirs by summer. — NYT: Top Stories
Business, Healthcare
Pathline Labs doubles testing capacity for COVID-19, adds major clients throughout U. S.
Pathline Labs Doubles Testing Capacity for COVID-19, Adds Major Clients Throughout U.S., Testing through Pathline Labs is now available nationwide RAMSEY, N.J.–(BUSINESS WIRE)–Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining
Healthcare, News Now!
Covid-19 news: Live updates
The staggering toll of the pandemic comes as at least 73 countries are seeing surges in newly detected cases. — NYT: Top Stories
Business, Healthcare
LYNPARZA reduced risk of death by 31% vs. Enzalutamide or Abiraterone for men with BRCA1/2 or ATM-mutated metastatic castration resistant prostate cancer who progressed following enzalutamide or abiraterone in Phase 3 PROfound trial
LYNPARZA is the Only PARP Inhibitor to Demonstrate Improved Overall Survival in Metastatic Castration-Resistant Prostate Cancer KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound
Business, Healthcare
Merck presents promising new data for three investigational medicines from diverse and expansive oncology pipeline at ESMO Virtual Congress 2020
Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor) Merck to Initiate Phase 3 Study of Vibostolimab in Non-Small
Business, Healthcare, Local News
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) demonstrates significant survival benefits in patients with advanced Renal Cell Carcinoma in pivotal Phase 3 CheckMate -9ER trial
Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium
Business, Healthcare
Merck’s KEYTRUDA® (pembrolizumab) reduced the risk of distant metastasis or death by 40% versus placebo as adjuvant treatment in resected, high-risk stage III melanoma
Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer